Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Vaccine Inactivated; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza, Human
Interventions: Elderberry Extract, Placebos; Drug
Lead sponsor: michael macknin; Other
Eligibility: 5 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza
Interventions: DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra); Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Carmichael, California • Chula Vista, California • La Mesa, California + 39 more

Conditions: Influenza A Virus Infection
Interventions: H2N3 MO 2003/AA ca Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 42 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 51
States / cities: Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more

Conditions: Influenza
Interventions: Influenza A/H7N7 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza Vaccination
Interventions: Question (Q), Messaging (M); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: San Francisco, California • Durham, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions: pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Mucosal Immune Response to Influenza Vaccination
Interventions: FluMist (Live Attenuated Influenza Vaccine); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Grippe, Influenza, Vaccines
Interventions: pdmFlu vaccine, Placebo, Licensed influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Hollywood, Florida • New York, New York

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,022 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more

Conditions: Influenza
Interventions: PanBlok, rHA adjuvant; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 341 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Omaha, Nebraska • Rochester, New York • Austin, Texas + 2 more

Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxoviridae, H5N1 Virus
Interventions: VRC-AVIDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: FLUARIX QUADRIVALENT; Biological
Lead sponsor: Emory University; Other
Eligibility: 42 Years to 71 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Baloxavir Marboxil, Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Harrisburg, Arkansas • Jonesboro, Arkansas + 22 more

Conditions: Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness, Cold
Interventions: Elderberry, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 20 Years to 65 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions: Bronchoscopy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Fluzone®: Influenza virus vaccine 2004-2005 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more

Conditions: Influenza-Like Illness, Influenza
Interventions: Core Lab Test, ED Point of Care Test; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: CAIV-T 10^7, CAIVT 10^5, Placebo, TIV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 2
States / cities: New Port Richey, Florida • Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Quadrivalent seasonal influenza vaccine GSK2282512A, Fluarix™ VB, Fluarix™ YB; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 3,109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 16
States / cities: Chandler, Arizona • Scottsdale, Arizona • Harrisburg, Arkansas + 13 more

Conditions: Influenza, Human
Interventions: NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 65 Years and older
Enrollment: 1,375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more

Search by objective public record fields.

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

How Healthy Adults Respond to the Nasal Flu Vaccine

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

H5 Vaccine Alone or With Adjuvant in Healthy Adults

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Safety Study of Avian Flu Vaccine

The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Elderberry for Immune Support

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Impact of Rapid Flu Testing in BMC ED

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults